In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them
[PMC free article: PMC6416709] [PubMed: 30576428] 42
Regenerative and Protective Actions of the GHK-Cu peptide in human tissues (Pickart et al., 2018) GHK-Cu supports tissue repair, stimulates collagen and elastin production, and encourages new blood vessel and nerve growth
Br J Cancer 96(12):17881795 Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Research Potential of TB-500 & BPC-157 Blend on Attenuating Inflammatory Signaling Laboratory work by Santra and colleagues suggests that TB-500 might support early inflammatory signals in research models
GHK-Cu Copper Peptide for Skin, Hair & Nails: GHK-Cu is a naturally occurring copper peptide that helps support collagen for skin elasticity and hair vitality
